CureVac Patent Suit Targets Moderna’s Spikevax Covid-19 Shots

robot
Abstract generation in progress

CureVac SE has filed a lawsuit against Moderna Inc., alleging that Moderna’s Spikevax Covid-19 vaccines infringe on 10 of CureVac’s patents. The German biotech firm claims that Spikevax—including its original, Omicron-targeting, and updated seasonal formulas—uses CureVac’s underlying mRNA composition, lipid nanoparticle formulation, and manufacturing processes. CureVac is seeking a reasonable royalty from Moderna’s global Spikevax sales, which exceed $47.7 billion.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned